Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have discovered sulfanilamide compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and ciliopathy.
Shenzhen Bay Laboratory has synthesized fused ring derivatives acting as dihydrofolate reductase (DHFR) (bacterial) inhibitors reported to be useful for the treatment of cancer, bacterial, fungal, nematode and viral infections.
Pfizer Inc. has identified new indole analogues acting as sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease (NAFLD; MASLD), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism-spectrum disorders, among others.
Confo Therapeutics NV has secured a 2-year €1 million (US$1.2 million) grant from Flanders Innovation & Entrepreneurship (VLAIO) to advance research and development of ultra-long-acting medicines targeting G protein-coupled receptors (GPCRs), including bi- and multispecific antibody formats for obesity and other metabolic and endocrine disorders.
Nilo Therapeutics Inc. has launched with a $101 million series A financing and a focus on harnessing neural circuits to restore immune homeostasis in disease.
Researchers at Hefei Amvite Pharmaceutical Co. Ltd. reported the discovery and preclinical evaluation of a series of structurally modified ziritaxestat derivatives, leading to the identification of more potent autotaxin inhibitors.
A new study aimed to investigate the therapeutic effect of ISM012-042 in a chronic T-cell transfer-induced colitis model in mice that mimicked Crohn’s disease.
Tessera Therapeutics Inc. has been awarded up to $41.3 million from the Advanced Research Projects Agency for Health (ARPA-H) as part of its EMBODY (Engineering of immune cells inside the body) program to support the development of Tessera’s in vivo CAR T therapy efforts.
Boehringer Ingelheim Pharma GmbH & Co KG has signed an asset purchase agreement with Accent Therapeutics Inc. for Accent’s preclinical small-molecule program that offers a novel approach for treating tumors with high interferon-stimulated gene (ISG) expression.
RSS
